Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Phase 3

Terminated

• Conditions: Anemia; Cancer

• Registration Number: NCT00083434
• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Brief Summary

The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-02
• Study First Submitted: 2004-05-24
• Study First Submitted QC: 2004-05-25
• Study First Posted: 2004-05-26
• Study Completion: 2004-10
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-25
• Last Update Posted: 2011-04-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• 18 years of age or older
• Body weight >/= 99lbs
• ECOG 0-2
• Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
• Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

Exclusion Criteria

• History of or concurrent second malignancy
• Evidence of primary or metastatic malignancy involving the Central Nervous System

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (6)

Madigan Army Medical Center Urology Services; 🇺🇸 Tacoma, Washington, United States

Hanover Medical Specialists, PA; 🇺🇸 Wilmington, North Carolina, United States

Advanced Urology Medical Center; 🇺🇸 Anaheim, California, United States

California Cancer Center; 🇺🇸 Fresno, California, United States

Shapiro, Stafford & Yee; 🇺🇸 Arcadia, California, United States

Tukoi Research; 🇺🇸 North Miami, Florida, United States